Comparative Pharmacology
Head-to-head clinical analysis: SELSUN versus TERCONAZOLE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SELSUN versus TERCONAZOLE.
SELSUN vs TERCONAZOLE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selenium sulfide is an antifungal agent that inhibits the growth of Malassezia species by reducing selenium to elemental selenium, which is toxic to the fungus. It also reduces sebum production via unknown mechanisms.
Terconazole is a triazole antifungal agent that inhibits fungal cytochrome P450 14α-demethylase, thereby blocking the conversion of lanosterol to ergosterol, an essential component of the fungal cell membrane. This disrupts membrane integrity and function.
Apply 5-10 mL of 2.5% selenium sulfide lotion to affected areas of scalp, lather with water, leave on for 2-3 minutes, then rinse thoroughly. Use twice weekly for 2 weeks, then once weekly for maintenance.
Intravaginal cream (0.4%, 0.8%): one applicatorful (approximately 5 g) intravaginally once daily at bedtime for 7 days; vaginal suppository (80 mg): one suppository intravaginally once daily at bedtime for 3 days.
None Documented
None Documented
Clinical Note
moderateTerconazole + Tranilast
"The risk or severity of adverse effects can be increased when Terconazole is combined with Tranilast."
Clinical Note
moderateTerconazole + Tolfenamic acid
"The risk or severity of adverse effects can be increased when Terconazole is combined with Tolfenamic acid."
Clinical Note
moderateTerconazole + Nimesulide
"The risk or severity of adverse effects can be increased when Terconazole is combined with Nimesulide."
Clinical Note
moderateTerconazole + Risedronic acid
Not well defined due to minimal systemic absorption; topical application yields negligible plasma levels.
Terminal elimination half-life is approximately 25-37 hours, allowing once-daily dosing for vaginal infections.
Selenium sulfide is minimally absorbed; absorbed portions are excreted renally (approx. 80-90%) and fecally (10-20%).
Primarily hepatic metabolism with biliary excretion; approximately 60-80% of the dose is excreted in feces as metabolites, and about 20% in urine mostly as inactive metabolites.
Category C
Category A/B
Antifungal/Antiseborrheic
Antifungal
"The risk or severity of adverse effects can be increased when Terconazole is combined with Risedronic acid."